After verifying the expression of CB1 and CB2 in the 7 established primary cell lines (Fig. 4E), we then moved to select individual glioma patient-derived cells with different CB1 receptor protein levels to characterize their sensitivity to SR141716 treatment on the basis of these receptors levels. The gene discussed is CNR2; the disease is glioma.